Mabion S.A. (MAB) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.308x

Based on the latest financial reports, Mabion S.A. (MAB) has a cash flow conversion efficiency ratio of -0.308x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-12.06 Million ≈ $-3.32 Million USD) by net assets (zł39.09 Million ≈ $10.76 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Mabion S.A. market cap and net worth for the company's overall valuation and market capitalisation.

Mabion S.A. - Cash Flow Conversion Efficiency Trend (2009–2025)

This chart illustrates how Mabion S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

Mabion S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Mabion S.A. ranked by their cash flow conversion efficiency. Explore Mabion S.A. cash earnings quality to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Inbest Prime IV Inmuebles SOCIMI S.A.
MC:YINB4
N/A
Kriti Industries (India) Limited
NSE:KRITI
-0.022x
Gol Linhas Aéreas Inteligentes S.A
NYSE:GOLLQ
-0.024x
Iconic Worldwide Bhd
KLSE:9113
0.028x
Carnival PLC
LSE:CCL
0.096x
ALPHA EXPLORATION LTD
F:J0C
-0.010x
Urbanfund Corp
V:UFC
0.028x
Metallic Minerals Corp
V:MMG
-0.327x

Annual Cash Flow Conversion Efficiency for Mabion S.A. (2009–2025)

The table below shows the annual cash flow conversion efficiency of Mabion S.A. from 2009 to 2025. View latest Mabion S.A. stock price today for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 zł55.35 Million
≈ $15.23 Million
zł-41.59 Million
≈ $-11.45 Million
-0.751x -310.06%
2024-12-31 zł111.44 Million
≈ $30.67 Million
zł39.86 Million
≈ $10.97 Million
0.358x +1905.77%
2023-12-31 zł117.78 Million
≈ $32.41 Million
zł-2.33 Million
≈ $-642.08K
-0.020x -103.90%
2022-12-31 zł76.51 Million
≈ $21.06 Million
zł38.84 Million
≈ $10.69 Million
0.508x +182.24%
2021-12-31 zł53.31 Million
≈ $14.67 Million
zł-32.91 Million
≈ $-9.06 Million
-0.617x -235.56%
2020-12-31 zł-77.39 Million
≈ $-21.30 Million
zł-35.24 Million
≈ $-9.70 Million
0.455x -70.89%
2019-12-31 zł-21.58 Million
≈ $-5.94 Million
zł-33.76 Million
≈ $-9.29 Million
1.564x +269.28%
2018-12-31 zł42.14 Million
≈ $11.60 Million
zł-38.94 Million
≈ $-10.72 Million
-0.924x -192.46%
2017-12-31 zł-54.16 Million
≈ $-14.91 Million
zł-54.13 Million
≈ $-14.90 Million
0.999x +124.49%
2016-12-31 zł3.73 Million
≈ $1.03 Million
zł-15.22 Million
≈ $-4.19 Million
-4.082x -1433.70%
2015-12-31 zł127.64 Million
≈ $35.13 Million
zł-33.97 Million
≈ $-9.35 Million
-0.266x -988.98%
2014-12-31 zł997.84 Million
≈ $274.62 Million
zł-24.39 Million
≈ $-6.71 Million
-0.024x +53.89%
2013-12-31 zł520.55 Million
≈ $143.26 Million
zł-27.59 Million
≈ $-7.59 Million
-0.053x -615.46%
2012-12-31 zł1.82 Billion
≈ $502.09 Million
zł-13.51 Million
≈ $-3.72 Million
-0.007x +98.71%
2011-12-31 zł20.37 Million
≈ $5.60 Million
zł-11.74 Million
≈ $-3.23 Million
-0.576x -794.40%
2010-12-31 zł21.72 Million
≈ $5.98 Million
zł-1.40 Million
≈ $-385.19K
-0.064x -101.62%
2009-12-31 zł-74.80K
≈ $-20.59K
zł-298.41K
≈ $-82.13K
3.990x --

About Mabion S.A.

WAR:MAB Poland Biotechnology
Market Cap
$33.85 Million
zł123.00 Million PLN
Market Cap Rank
#23463 Global
#224 in Poland
Share Price
zł7.61
Change (1 day)
-2.93%
52-Week Range
zł6.82 - zł9.63
All Time High
zł134.60
About

Mabion S.A., a biopharmaceutical company, provides contract development, analytics, and manufacturing services for biologics in Poland. It offers drug substance manufacturing, process development, analytics, and cell line development services. The company also provides medicines for cancer, autoimmune diseases, rare diseases, and other diseases. The company was founded in 2007 and is headquartere… Read more